Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy

Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy

Abstract Background 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a decrease in left ventricular ejection fraction. The aim of this study is...

Full description

Bibliographic Details
Main Authors: Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc, Gregory Aune
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cardio-Oncology
Subjects:
Predictive Model
Cardiotoxicity
Trastuzumab
Breast Cancer
Online Access:https://doi.org/10.1186/s40959-023-00177-y

Internet

https://doi.org/10.1186/s40959-023-00177-y

Similar Items